US5169642A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained-release drug dosage units
Assignee: Abbott Laboratories
•
Filing: 1991-06-04
•
Granted: 1992-12-08
•
Expires: 2011-06-04
Abstract
Abstract A sustained-release coating composition is described that contains an ethylcellulose and/or a methacrylic methylester together with a plasticizer and a detackifying agent. Sized drug granules are coated with this composition and then mixed with a polymeric composition containing at least one viscosity agent and formed into drug dosage units for the administration and sustained release of the drug in a patient. The sustained-release drug dosage units described produce a continuous, slow release of the drug at a therapeutically effective dosage level when administered to a patient.
Inventors
- 👤 Dale R. Brinker
- 👤 Enrique D. Eveline
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 02:27
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5073; A61K9/20; A61K9/2072; A61K9/2077; A61K9/2081
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
82 words
A sustained-release drug dosage form comprising (1) granules of divalproex sodium, valproic acid or amides or esters or salts thereof coated with a sustained-release coating composition comprising from about 2 to about 20 weight percent (w/v) of an ethylcellulose or a methacrylic methylester, from about 0.1 to about 5.0 weight percent (w/v) of a plasticizer and from about 0.5 to about 20 weight percent (w/v) of a detackifying agent and (2) a slow release matrix comprising at least one polymeric viscosity agent.
Claim 2
Dependent Claim
82 words
A sustained-release drug dosage form comprising (1) granules of divalproex sodium, valproic acid or amides or esters or salts thereof coated with a sustained-release coating composition comprising from about 2 to about 20 weight percent (w/v) of an ethylcellulose or a methacrylic methylester, from about 0.1 to about 5.0 weight percent (w/v) of a plasticizer and from about 0.5 to about 20 weight percent (w/v) of a detackifying agent and (2) a slow release matrix comprising at least one polymeric viscosity agent.
Claim 3
Dependent Claim
34 words
The drug dosage form of claim 1, wherein said plasticizer is selected from the group consisting of castor oil, propylene glycol, polyethylene glycol, acetyl triethyl citrate, acetyl tributyl citrate, triethyl citrate and tributyl citrate.
Claim 4
Dependent Claim
26 words
The drug dosage form of claim 1, wherein said detackifying agent is selected from the group consisting of magnesium stearate, talc, titanium dioxide and silica gel.
Claim 5
Dependent Claim
48 words
The drug dosage form of claim 1 wherein the coating composition comprises from about 2 to about 20 weight percent (w/v) of ethylcellulose, from about 0.1 to about 5.0 weight percent (w/v) of castor oil and from about 0.5 to about 20 weight percent (w/v) of magnesium stearate.
Claim 6
Dependent Claim
23 words
The drug dosage form of claim 1 wherein said viscosity agent is selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, povidone and hydroxypropylcellulose.
Claim 7
Dependent Claim
74 words
The drug dosage form of claim 1 comprising: about 2.0 to about 80 weight percent sustained release coated drug granules; about 0 to about 30 weight percent calcium phosphate; about 2 to about 30 weight percent of a first viscosity agent and about 0 to about 30 weight percent of a second viscosity agent wherein said first and second viscosity agents are independently selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, povidone and hydroxypropylcellulose.
Claim 8
Dependent Claim
75 words
The drug dosage form of claim 1 comprising: from about 63 to about 65 weight percent of sustained-release coated divalproex sodium granules; from about 3.5 to about 4.5 weight percent of methylcellulose; from about 14.2 to about 14.6 weight percent of hydroxypropylmethylcellulose; from about 14.2 to about 14.6 weight percent of calcium phosphate; from about 0.7 to about 0.8 weight percent of stearic acid; and from about 1.5 to about 2.2 weight percent of talc.
References Cited (Backward Citations)
US4138475A
Cited
US4199560A
Cited
US4351825A
Cited
US4252786A
Cited
EP0092060A1
Cited
US4572833A
Cited
EP0133110A1
Cited
US4555399A
Cited
US4713248A
Cited
US4716041A
Cited
US4913906A
Cited
US4913906B1
Cited
US4772475A
Cited
US4874614A
Cited
US4786506A
Cited
US4756911A
Cited
AU2472788A
Cited
EP0347748A2
Cited
EP0385846A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-12-08 | 1996-06-08 | 1996-12-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-12-08 | 2000-06-08 | 2000-12-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-12-08 | 2004-06-08 | 2004-12-08 | $7700.00 | Window Closed / Lapsed |